{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2017-21202:v1","objectPathId":"federal-register-2017-21202-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2017-21202/","json":"https://peptidescanner.com/evidence/v1/objects/federal-register-2017-21202-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/federal-register-2017-21202-v1.md"},"story":{"slug":"federal-register-2017-21202","version":1,"domain":"Regulatory","dateInSource":"2017-10-03","sourceCheckedAt":"2026-08-21","publishedAt":"2026-08-21","peptideSlugs":["glucagon","liraglutide","teriparatide"],"peptides":[{"slug":"glucagon","url":"https://peptidescanner.com/peptides/glucagon/"},{"slug":"liraglutide","url":"https://peptidescanner.com/peptides/liraglutide/"},{"slug":"teriparatide","url":"https://peptidescanner.com/peptides/teriparatide/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2017-21202","sourceIds":["federal-register-2017-21202-c4f4d0d80056"]},{"id":"summary","text":"The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.","sourceIds":["federal-register-2017-21202-c4f4d0d80056"]},{"id":"paragraph-1","text":"The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.","sourceIds":["federal-register-2017-21202-c4f4d0d80056"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2017-21202-c4f4d0d80056"]}],"sources":[{"id":"federal-register-2017-21202-c4f4d0d80056","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2017-21202 · published 2017-10-03 · Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability","url":"https://www.govinfo.gov/content/pkg/FR-2017-10-03/pdf/2017-21202.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"67006fdca05d88999a322e9ecb4d3fea0131f0aa854582fe9c826630f7a872af","tierARecordSha256":"c4f4d0d80056a5312bc945f6f7012c59740026350aaeea6ddbbf699e5f4d90bb"},"integrity":{"algorithm":"sha256","contentSha256":"74b5b6d0959fa74fec1324c1ed7e2f0d434b19a91ab3945390938d9358b2d6d6"}}